Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole.
A 25-year-old male with chronic granulomatous disease developed severe bilateral pulmonary aspergillosis confirmed by a positive result of polymerase chain reaction for Aspergillus species from sputum and positive serological tests for Aspergillus. He was successfully treated with voriconazole. The diagnostic difficulties and the new therapeutic options in the era of new antifungal agents are discussed.
Sambatakou
H
H
Education and Research Centre, Wythenshawe University Hospital, Southmoor Road, Manchester, M23 9LT, UK. helen2@otenet.gr
Guiver
M
M
Denning
D
D
D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage; D001228:Aspergillosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016469:Fungemia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006105:Granulomatous Disease, Chronic / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D016133:Polymerase Chain Reaction / Q000379:methods; D011743:Pyrimidines / Q000008:administration & dosage*; D012680:Sensitivity and Specificity; D012698:Serologic Tests; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole